Santaris Pharma this week announced that it has raised $12 million through the sale of convertible bonds to existing private investors and members of the company's management.
Santaris said that proceeds from the financing would primarily be used to fund the continued development of its microRNA-targeting hepatitis C drug miravirsen, which is under phase II development, as well as its pipeline of other locked nucleic acid-based therapeutic candidates.